COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targetedCOPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted

Curasight to present at TD Cowen’s 46th Annual Health Care Conference in Boston

Author: AI Journal

Source: AI Journal

2026/02/17 15:15

2 min read

1$0.0005296+18.53%

CPH$0.003815-3.61%

For feedback or concerns regarding this content, please contact us at [email protected]

COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46^th Annual Health Care Conference on Tuesday, March 3^rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is a major investor conference where public and private healthcare companies meet with institutional investors, and large pharma via scheduled 1×1 meetings and presentations combined with fireside chats and innovative panel discussions.

About Curasight A/S

Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
E-mail: [email protected]
www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454

The following files are available for download:

https://mb.cision.com/Main/19744/4308454/3937544.pdf

260217 Curasight Press release – TDCowen

View original content:https://www.prnewswire.com/news-releases/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston-302689307.html

SOURCE Curasight

Market Opportunity

Ucan fix life in1day Price(1)

$0.0005296

$0.0005296$0.0005296

+1.55%

USD

Ucan fix life in1day (1) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.